Praetego
Praetego to Present Latest PTG-630 Alzheimer’s data at BIO 2024 in San Diego
Praetego is excited to present the latest data from its lead Amadorin candidate, PTG-630, at the BIO International Convention in San...
top of page
Praetego
Dec 14, 2023
Praetego’s PTG-630 Successfully Completes a Pre-IND Meeting with the FDA’s Division of Neurology
Praetego successfully completed a Pre-IND meeting with the FDA’s Division of Neurology for PTG-630
Praetego
Mar 1, 2023
Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy
Praetego Inc, a pharmaceutical company protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $0.3M
Praetego
Oct 4, 2022
Praetego Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer’s Disease
Praetego Inc, a pharmaceutical company committed to protecting patients from neurodegenerative diseases related to aging, is pleased to anno
Praetego
Sep 30, 2021
Praetego Wins RESI Longevity Innovator’s Pitch Challenge
Praetego presented to the Innovator’s Pitch Challenge at RESI Longevity in September 2021 and came away with the win. The Redefining...
Praetego
Jul 14, 2021
Life Science Nation Interview
After being a winner in the Digital RESI June Innovator’s Pitch Challenge, Praetego’s CEO Pepper Landson is interviewed by Life Science Nati
Praetego
Apr 26, 2021
2021 Health Innovation Hub: Life Science Cohort Announced
Praetego’s CEO, Pepper Landson, is honored to be invited to Springboard Enterprises’ 2021 Health Innovation Hub: Life Science cohort.
Praetego
Sep 30, 2020
NIH Phase 2 STTR Funding Award
Praetego Inc. is pleased to announce the approval of a multi-year $2.1M STTR grant from the National Institute of Diabetes and Digestive and
Praetego
Mar 1, 2020
Praetego to present at the Venture Connect Summit in Raleigh NC
Praetego will showcase their candidates as potential disease modifying drugs against serious diabetic complications, starting with Diabetic
Praetego
Jan 2, 2020
Phase 2 grant submitted to NIH/NIDDK
After a successful conclusion of the Phase 1 NIDDK grant, Praetego submits a Phase 2 SBIR/STTR grant.
Press + Announcements
Praetego’s progress is routinely updated as we strive to enter clinical trials. Please check back frequently for news, announcements, and events.
bottom of page